Antiviral drugs (AvDs) are the primary resource in the global battle against viruses, including
the recent fight against corona virus disease 2019 (COVID-19). Most AvDs require multiple …

Highlights•Inhaled medicines are cornerstones in the treatment of asthma/COPD
today.•Significant unmet medical need remains in the treatment of respiratory diseases.•The …

RV521 is an orally bioavailable inhibitor of respiratory syncytial virus (RSV) fusion that was
identified after a lead optimization process based upon hits that originated from a physical …

Respiratory syncytial virus (RSV) is a globally prevalent viral infection with limited treatment
options which hospitalizes millions each year. Treatment options have been limited to …

The long-term control strategy of SARS-CoV-2 and other major respiratory viruses needs to
include antivirals to treat acute infections, in addition to the judicious use of effective …

Background PC786 is a nebulized nonnucleoside respiratory syncytial virus (RSV)
polymerase inhibitor designed to treat RSV, which replicates in the superficial layer of …

This review provides an update for the international research community on the cell
modeling tools that could accelerate the understanding of SARS-CoV-2 infection …

Small airway infections caused by respiratory viruses are some of the most prevalent causes
of illness and death. With the recent worldwide pandemic due to the severe acute respiratory …

Background Elderly people are known to be vulnerable to virus infection. However, this has
not been appropriately tested in in vitro studies due to a lack of appropriate virus infection …

Respiratory viral infections, including severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2), are among the most common illnesses and a leading cause of morbidity and …